AstraZeneca submitted a non-binding offer of approximately $10 billion, offering up to $134 per share with milestone achievements, to acquire obesity drugmaker Rhythm Pharmaceuticals. The proposed takeover would be executed through AstraZeneca's rare-disease unit Alexion. The deal aims to establish AstraZeneca's presence in the booming obesity treatment market while CEO Pascal Soriot seeks to restore investor confidence following recent clinical trial setbacks.
AstraZeneca's acquisition offer for Rhythm
- ▪AstraZeneca offered $124 per share for Rhythm Pharmaceuticals last month prior to adding milestone payments to its $10 billion offer
- ▪Shares of Rhythm Pharmaceuticals closed up 28% at $110.68 on November 4, 2026 following reports of AstraZeneca's acquisition offer, giving Rhythm a market capitalization of about $7.64 billion
- ▪AstraZeneca made a non-binding offer of approximately $10 billion, or up to $134 a share including milestone payments, to acquire obesity drugmaker Rhythm Pharmaceuticals
Strategic rationale for AstraZeneca's bid
- ▪AstraZeneca plans to pursue its proposed $10 billion acquisition of Rhythm Pharmaceuticals through Alexion, its rare-disease unit acquired for $39 billion in 2021
- ▪Jefferies analyst Michael Leuchten stated that AstraZeneca's approach of seeking rare disease assets fitting its existing footprint is sensible
- ▪Acquiring Rhythm Pharmaceuticals would provide AstraZeneca with an established commercial presence in obesity while expanding its rare-disease portfolio
Story comments
Loading comments…